Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning
A Deep Learning Model Based on Contrast-enhanced Ultrasound to Aid Clinical Decisions and Predict Biological Biomarker and Prognosis of Hepatocellular Carcinoma
1 other identifier
observational
1
1 country
1
Brief Summary
Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
February 13, 2022
CompletedFirst Posted
Study publicly available on registry
February 25, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedOctober 21, 2022
October 1, 2022
4 years
February 13, 2022
October 19, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Recurrence-free survival (RFS)
Recurrence-free survival is defined as the time elapsed between a predefined point in time (the date of diagnosis, randomization or the intervention) and any recurrence (local, regional, or distant) or death due to any cause (death is an event).
Immediately after the surgery or ablation
Secondary Outcomes (1)
Recurrence
Immediately after the surgery or ablation
Interventions
hepatectomy
image-guided ablation
Eligibility Criteria
patients with HCC corresponding to Ia, Ib, IIa stage (China liver cancer staging) who undergo resection or ablation.
You may qualify if:
- patients with HCC (Ia, Ib, IIa stage) China liver cancer staging who underwent resection or ablation
- without macro-vascular invasion
- Child-Pugh A/B grade
- HCC is proved by pathological examination or two enhanced imaging
- CEUS (Sonovue or Sonozoid) images are performed two weeks before the operation
- Invasive biomarker or prognosis of HCC available
- CEUS images are included in at least three stages (Arterial phase, Portal phase, and Late phase)
You may not qualify if:
- postop follow-up loss or expired less than 3 months
- patients with co-malignancy
- poor images quality for analyzing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ping Lianglead
Study Sites (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Chief of department of interventional ultrasound
Study Record Dates
First Submitted
February 13, 2022
First Posted
February 25, 2022
Study Start
January 1, 2022
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
October 21, 2022
Record last verified: 2022-10